Skip to main content
TipRanks
Go Ultimate75% OFF

aap Implantate (AAQ1) AI Stock Analysis

2 Followers
DE:AAQ1

aap Implantate

(XETRA:AAQ1)

Select Model
Rating:40Underperform
Price Target:EUR 1.50â–²(7.91% Upside)
Action:downgraded
Date:11/07/26

The overall score is constrained primarily by persistent losses and negative cash generation, with additional pressure from bearish technical trends and a negative P/E ratio. Low leverage and strong gross profitability provide some support but are not sufficient to offset the lack of sustainable profitability and cash flow.

Positive Factors
Strong Gross MarginAn approximately 82% gross margin indicates strong product-level economics in the company’s orthopedic implant activities. This provides a substantial base to absorb operating costs, support product development, and potentially improve profitability if revenue scale and cost discipline strengthen over the next several quarters.
Negative Factors
Persistent UnprofitabilityContinued net losses show that strong gross profitability is not currently sufficient to cover the company’s operating cost base. Persistently negative returns on equity also indicate that capital is not yet compounding through earnings, limiting internal funding capacity and weakening long-term financial resilience.

aap Implantate (AAQ1) vs. iShares MSCI Germany ETF (EWG)

-20%-10%0%10%20%30%40%50%60%DE:AAQ1-2.11%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 22.52M
Dividend Yield
―
Average Volume (3M)
1,793
Price to Earnings (P/E)
-7.1
Beta (1Y)
-0.14
Revenue Growth
1.81%
EPS Growth
42.07%
Country
Germany
Employees
105
Sector
General
Sector Strength
55
Industry
Medical - Specialties

aap Implantate Business Overview & Revenue Model

Company Description

Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international reg...

How the Company Makes Money

aap Implantate generates revenue primarily by selling orthopedic/trauma implant systems and associated surgical instrumentation to healthcare providers (such as hospitals and surgical centers), either directly or via distribution partners. Key revenu...

aap Implantate Financial Statement Overview

Summary

Financial performance is weak overall: persistent operating and net losses, consistently negative operating and free cash flow, and recent revenue contraction outweigh the benefits of strong gross profitability and relatively low leverage.

Income Statement

35Negative

Balance Sheet

60Neutral

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Jun 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue12.78M12.50M12.20M11.48M11.52M12.17M
Gross Profit11.38M10.80M10.67M9.74M10.58M2.32M
EBITDA-815.20K-632.00K-1.19M-3.43M-1.57M-520.00K
Net Income-2.73M-2.60M-3.63M-5.13M-2.56M-2.52M
Balance Sheet
Total Assets16.11M13.75M15.84M19.47M20.23M22.95M
Cash, Cash Equivalents and Short-Term Investments286.00K1.40M2.46M1.64M236.00K2.11M
Total Debt3.97M984.00K1.72M5.29M3.17M5.08M
Total Liabilities7.93M5.06M5.38M8.63M7.40M10.18M
Stockholders Equity8.18M8.70M10.46M10.85M12.83M12.78M
Cash Flow
Free Cash Flow-1.78M-2.16M-1.45M-3.40M-2.38M-2.99M
Operating Cash Flow-1.33M-1.43M-1.12M-2.99M-1.89M-2.47M
Investing Cash Flow-876.00K-670.00K-327.00K-397.00K-469.00K155.00K
Financing Cash Flow2.27M859.00K2.22M4.42M475.00K3.53M

aap Implantate Technical Analysis

Technical Analysis SentimentNegative
Last Price1.39

Price Trends

50DMA1.57Negative
100DMA1.58Negative
200DMA1.63Negative

Market Momentum

MACD-0.04Negative
RSI35.95Neutral
STOCH34.17Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AAQ1, the sentiment is Negative. The current price of 1.39 is below the 20-day moving average (MA) of 1.44, below the 50-day MA of 1.57, and below the 200-day MA of 1.63, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 35.95 is Neutral, neither overbought nor oversold. The STOCH value of 34.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:AAQ1.

aap Implantate Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:AAQ1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:AFXDE:AFX73OutperformEUR 3.13B20.965.52%1.57%-0.06%-38.81%
DE:EUZDE:EUZ67NeutralEUR 959.88M17.6321.30%1.43%4.05%36.66%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
DE:GMEDE:GME45NeutralEUR 10.89M-14.33-4.38%5.00%1.58%-148.73%
DE:AAQ1DE:AAQ140UnderperformEUR 22.52M-7.13-32.36%―1.81%42.07%

* General Sector Average

Performance Comparison

-50%0%50%DE:AAQ1DE:AFXDE:EUZDE:GMEDE:E8XDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:AAQ1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:AAQ1aap Implantate1.39-0.03-2.11%
DE:AFXCarl Zeiss Meditec35.00-5.49-13.56%
DE:EUZEckert & Ziegler Strahlen und Medizintechnik15.34-0.52-3.29%
DE:GMEGeratherm Medical2.00-1.27-38.74%
DE:MF6MagForce AG―――
DE:E8Xelexxion AG0.01-0.11-89.60%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026